GBI_Logo.jpg
Genius Brands International Announces $2.8 Million Registered Direct Offering
May 07, 2020 09:15 ET | Genius Brands International, Inc.
BEVERLY HILLS, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Genius Brands International, Inc. (“Genius Brands” or the “Company”) (NASDAQ: GNUS) announced today that it has entered into a securities...
Akers Bio logo
Akers Biosciences Announces $4.6 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
April 07, 2020 10:53 ET | Akers Biosciences Inc.
Thorofare, New Jersey, April 07, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has...
Emerald Logo.png
Emerald Bioscience Announces $2.0 Million Registered Direct Offering
November 21, 2019 09:12 ET | Emerald Bioscience, Inc.
Long Beach, CA, Nov. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based...
ifreshlogo.png
iFresh, Inc. Announces Pricing of Approximately $2.6 Million Registered Direct Offering
October 19, 2018 09:34 ET | iFresh, Inc
NEW YORK, Oct. 19, 2018 (GLOBE NEWSWIRE) -- iFresh, Inc. (“iFresh” or “the Company”) (NASDAQ:IFMK), a leading Asian American grocery supermarket chain and online grocer, announced today it has...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Closing of Public Offering and Concurrent Registered Direct Offering of Common Shares
October 31, 2017 08:30 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares
October 25, 2017 16:01 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...